Search
  • English
  • 中文
flash1
  • About Us
    • At a Glance
    • History
    • Recognition
    • Management Team
  • Research & Development
    • Oncology
    • Immunology
  • Pipeline
  • Partnership
    • Overview
    • Existing Partnerships
  • News & Publications
    • Press Releases
    • Publications
  • Careers
    • Employment Opportunities
    • Cultural Activities
  • Contacts
Press Releases
05-Sep-2018
HMP Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China
23-Jul-2018
HMP Initiates a Phase Ib/II Proof-of-Concept Trial of Sulfatinib in Pancreatic Neuroendocrine Tumors and Biliary Tract Cancer in the United States
04-Jun-2018
HMP Presents Further Fruquintinib FRESCO Trial Data at ASCO 2018 Annual Meeting
06-Mar-2018
HMP Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China
13-Feb-2018
HMP Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer
15-Dec-2017
HMP Initiates Fruquintinib U.S. Clinical Trials
31-Oct-2017
HMP Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line Gastric Cancer
17-Oct-2017
HMP and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification
16-Oct-2017
HMP Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer
12-Oct-2017
Appointment of Director
12345...1020...»»
  • Disclaimer
  • Sitemap
    •
    Copyright ©2018 Hutchison MediPharma Limited. All rights reserved.